[{"orgOrder":0,"company":"United Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"United Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"United Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"United Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Essential Pharma","sponsor":"AGC Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"Essential Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Essential Pharma \/ AGC Biologics","highestDevelopmentStatusID":"8","companyTruncated":"Essential Pharma \/ AGC Biologics"},{"orgOrder":0,"company":"St. Jude Children","sponsor":"Renaissance Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Licensing Agreement","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"St. Jude Children","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"St. Jude Children \/ Renaissance Pharma","highestDevelopmentStatusID":"8","companyTruncated":"St. Jude Children \/ Renaissance Pharma"},{"orgOrder":0,"company":"BeOne Medicines","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I","graph3":"BeOne Medicines","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"BeOne Medicines \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"BeOne Medicines \/ Inapplicable"},{"orgOrder":0,"company":"Apeiron Biologics","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Antibody","year":"2024","type":"Acquisition","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Apeiron Biologics","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Apeiron Biologics \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Apeiron Biologics \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"BeOne Medicines","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2020","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ BeiGene","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ BeiGene"},{"orgOrder":0,"company":"Eusa Pharma","sponsor":"Recordati","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Antibody","year":"2021","type":"Acquisition","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Approved FDF","graph3":"Eusa Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Eusa Pharma \/ Recordati","highestDevelopmentStatusID":"15","companyTruncated":"Eusa Pharma \/ Recordati"},{"orgOrder":0,"company":"Children's Hospital Los Angeles","sponsor":"United Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2022","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase IV","graph3":"Children's Hospital Los Angeles","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Children's Hospital Los Angeles \/ United Therapeutics","highestDevelopmentStatusID":"11","companyTruncated":"Children's Hospital Los Angeles \/ United Therapeutics"},{"orgOrder":0,"company":"IKF Nordwest","sponsor":"Recordati","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2021","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase II","graph3":"IKF Nordwest","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IKF Nordwest \/ Recordati","highestDevelopmentStatusID":"8","companyTruncated":"IKF Nordwest \/ Recordati"},{"orgOrder":0,"company":"Children's Oncology Group","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Bone Marrow Aspiration","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Children's Oncology Group","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Children's Oncology Group \/ National Cancer Institute","highestDevelopmentStatusID":"8","companyTruncated":"Children's Oncology Group \/ National Cancer Institute"},{"orgOrder":0,"company":"New Approaches to Neuroblastoma Therapy Consortium","sponsor":"Nationwide Children\u2019s Hospital | United Therapeutics | Children's Neuroblastoma Cancer Foundation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"New Approaches to Neuroblastoma Therapy Consortium","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"New Approaches to Neuroblastoma Therapy Consortium \/ Nationwide Children\u2019s Hospital | United Therapeutics | Children's Neuroblastoma Cancer Foundation","highestDevelopmentStatusID":"8","companyTruncated":"New Approaches to Neuroblastoma Therapy Consortium \/ Nationwide Children\u2019s Hospital | United Therapeutics | Children's Neuroblastoma Cancer Foundation"},{"orgOrder":0,"company":"Princess Maxima Center for Pediatric Oncology","sponsor":"Eusa Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Dinutuximab","moa":"||Disialoganglioside GD2","graph1":"Oncology","graph2":"Phase I","graph3":"Princess Maxima Center for Pediatric Oncology","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Princess Maxima Center for Pediatric Oncology \/ EUSA Pharma","highestDevelopmentStatusID":"6","companyTruncated":"Princess Maxima Center for Pediatric Oncology \/ EUSA Pharma"}]

Find Clinical Drug Pipeline Developments & Deals for Dinutuximab beta

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : AGC Biologics will produce Hu1418K322A (Hu14.18), a humanised monoclonal antibody being developed for Essential Pharma for the treatment of high-risk neuroblastoma (HRNB).

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          November 06, 2024

                          Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : AGC Biologics

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Ligand acquires Apeiron Biologics pipeline which also includes Qarziba (dinutuximab beta), it is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above.

                          Product Name : Qarziba

                          Product Type : Antibody

                          Upfront Cash : $100.0 million

                          August 07, 2024

                          Lead Product(s) : Dinutuximab,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Ligand Pharmaceuticals

                          Deal Size : $128.0 million

                          Deal Type : Acquisition

                          blank

                          03

                          Princess Maxima Center for Pediatric Oncology

                          Country arrow
                          EPSC
                          Not Confirmed

                          Princess Maxima Center for Pediatric Oncology

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          July 03, 2024

                          Lead Product(s) : Dinutuximab,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Eusa Pharma

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          New Approaches to Neuroblastoma Therapy Consortium

                          Country arrow
                          EPSC
                          Not Confirmed

                          New Approaches to Neuroblastoma Therapy Consortium

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Universal Donor TGF-Beta Inhibited NK Cell,Temozolomide,Irinotecan Hydrochloride,Dinutuximab,GM-CSF

                          Therapeutic Area : Oncology

                          Study Phase : Phase II

                          Sponsor : Nationwide Children’s Hospital | United Therapeutics | Children's Neuroblastoma Cancer Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 10, 2024

                          Lead Product(s) : Universal Donor TGF-Beta Inhibited NK Cell,Temozolomide,Irinotecan Hydrochloride,Dinutuximab,GM-CSF

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Nationwide Children’s Hospital | United Therapeutics | Children's Neuroblastoma Cancer Foundation

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the agreement, Renaissance gains exclusive development, manufacturing and commercialisation rights for Hu14.18K322A, an anti GD2 humanised mAb in development by St. Jude for the treatment of newly diagnosed high-risk neuroblastoma.

                          Product Name : Undisclosed

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          January 08, 2023

                          Lead Product(s) : Dinutuximab,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Renaissance Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          06

                          Children's Hospital Los Angeles

                          Country arrow
                          EPSC
                          Not Confirmed

                          Children's Hospital Los Angeles

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          June 16, 2022

                          Lead Product(s) : Dinutuximab,Cyclophosphamide,Topotecan Hydrochloride,Temozolomide,Irinotecan Hydrochloride,Sagramostim

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase IV

                          Sponsor : United Therapeutics

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          May 13, 2022

                          Lead Product(s) : Dinutuximab,Isotretinoin

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          IKF Nordwest

                          Country arrow
                          EPSC
                          Not Confirmed

                          IKF Nordwest

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Inapplicable

                          October 18, 2021

                          Lead Product(s) : Dinutuximab,Zoledronic Acid,Interleukin-2

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : Recordati

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small ...

                          Product Name : Qarziba

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          March 12, 2021

                          Lead Product(s) : Dinutuximab,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : Recordati

                          Deal Size : $847.0 million

                          Deal Type : Acquisition

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : QARZIBA® is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells.

                          Product Name : Qarziba

                          Product Type : Antibody

                          Upfront Cash : Inapplicable

                          September 11, 2020

                          Lead Product(s) : Dinutuximab,Inapplicable

                          Therapeutic Area : Oncology

                          Highest Development Status : Approved FDF

                          Sponsor : BeOne Medicines

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank